ROCKVILLE, Md., May 17, 2023
/PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq:
SHPH), a discovery and development stage specialty pharmaceutical
company focused on improving outcomes for cancer patients treated
with radiation therapy (RT) (the "Company," or "Shuttle
Pharmaceuticals"), announced today that its Chief Executive
Officer, Anatoly Dritschilo, M.D.,
will be participating in a Webcast and Panel Presentation at the
Lytham Partners Spring 2023 Investor Conference (the
"Conference") on Thursday, May 18,
2023. Management will also be conducting one-on-one meetings
with investors.
Company Webcast
The Company's webcast presentation will be available for viewing
at 9:00 am ET on Thursday, May 18,
2023, on the Company's website at
https://shuttlepharma.com/investor-relations/ or
https://wsw.com/webcast/lytham8/shph/2045925. The webcast will also
be archived and available for replay.
Panel Presentation
Additionally, Dr. Dritschilo will be participating in a panel
titled, "Advancements in the Fight Against Cancer." This panel,
also to be conducted virtually, will be held on Thursday, May 18, 2023, at 11:00 am ET. To access the panel, please visit:
https://wsw.com/webcast/lytham8/panel2/2271150.
1x1 Meetings
Management will be participating in virtual one-on-one meetings
throughout the Conference. To arrange a meeting with management,
please contact Lytham Partners at 1x1@lythampartners.com or
register at
https://www.lythampartners.com/spring2023invreg/.
About Shuttle Pharmaceuticals
Founded in 2012 by faculty members of the Georgetown
University Medical Center, Shuttle Pharma is a discovery and
development stage specialty pharmaceutical company focused on
improving the outcomes for cancer patients treated with radiation
therapy (RT). Our mission is to improve the lives of cancer
patients by developing therapies that are designed to maximize the
effectiveness of RT while limiting the side effects of radiation in
cancer treatment. Although RT is a proven modality for treating
cancers, by developing radiation sensitizers, we aim to increase
cancer cure rates, prolong patient survival and improve quality of
life when used as a primary treatment or in combination with
surgery, chemotherapy and immunotherapy. For more information,
please visit our website at www.shuttlepharma.com.
Shuttle Pharmaceuticals
Contact: Anatoly Dritschilo, M.D., Chief Executive
Officer
Tel: 240-403-4212
Email: info@shuttlepharma.com
Investor Contacts
Lytham Partners, LLC
Contact: Robert Blum
Tel: 602-889-9700
Email: shph@lythampartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/shuttle-pharmaceuticals-to-participate-in-the-lytham-partners-spring-2023-investor-conference-301826786.html
SOURCE Shuttle Pharmaceuticals Holdings, Inc.